{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=90",
    "query": {
      "condition": "Advanced Stage Solid Tumors",
      "page": 90
    },
    "page_size": 10
  },
  "pagination": {
    "page": 90,
    "page_size": 10,
    "total_count": 3086,
    "total_pages": 309,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=91&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=89&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T06:25:35.124Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01358903",
      "title": "A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "RO5429083",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2011-06",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-11-22T06:25:35.124Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01358903"
    },
    {
      "nct_id": "NCT05789069",
      "title": "A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Melanoma",
        "Non Small Cell Lung Cancer",
        "Gastric Cancer",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "HFB200603",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HiFiBiO Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2023-05-09",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-11-22T06:25:35.124Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Philadelphia, Pennsylvania • Fairfax, Virginia",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05789069"
    },
    {
      "nct_id": "NCT02536469",
      "title": "HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "HuMax-IL8",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2015-08",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2017-02-03",
      "last_synced_at": "2026-11-22T06:25:35.124Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02536469"
    },
    {
      "nct_id": "NCT05571969",
      "title": "Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "2X-121 600 mg",
          "type": "DRUG"
        },
        {
          "name": "2X-121 800 mg",
          "type": "DRUG"
        },
        {
          "name": "2X-121 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "2X-121 + 300 mg dovitinib",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "2X-121 + 400 mg dovitinib",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "2X-121 + 500 mg dovitinib",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Allarity Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2023-03-08",
      "completion_date": "2024-10-07",
      "has_results": true,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-11-22T06:25:35.124Z",
      "location_count": 3,
      "location_summary": "Huntersville, North Carolina • Cleveland, Ohio • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05571969"
    },
    {
      "nct_id": "NCT02266745",
      "title": "A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "CRPC",
        "mCRPC",
        "Metastatic Castrate-resistant Prostate Cancer",
        "PT-112",
        "Prostatic Neoplasms",
        "Genital Neoplasms, Male",
        "Urogenital Neoplasms",
        "Neoplasms by Site"
      ],
      "interventions": [
        {
          "name": "PT-112 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Promontory Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 109,
      "start_date": "2014-07",
      "completion_date": "2025-04-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-05",
      "last_synced_at": "2026-11-22T06:25:35.124Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02266745"
    },
    {
      "nct_id": "NCT04902872",
      "title": "Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Epithelial Ovarian Cancer",
        "Small Cell Lung Carcinoma",
        "Breast Cancer",
        "Colorectal Cancer",
        "Pancreas Cancer",
        "Appendix Cancer",
        "Non-small Cell Lung Cancer",
        "Gastric Cancer",
        "Esophagus Cancer",
        "Urothelial Carcinoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "CBX-12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cybrexa Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2021-05-03",
      "completion_date": "2025-06-24",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-22T06:25:35.124Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Austin, Texas • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04902872"
    },
    {
      "nct_id": "NCT03805841",
      "title": "Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC, Stage IV",
        "NSCLC Stage IIIB",
        "NSCLC, Stage IIIC",
        "NSCLC, Recurrent",
        "EGFR Exon 20 Insertion Mutation",
        "HER2-activating Mutation",
        "ERBB Fusion",
        "NRG1 Fusion"
      ],
      "interventions": [
        {
          "name": "tarloxotinib bromide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rain Oncology Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2019-03-13",
      "completion_date": "2021-04-23",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-11-22T06:25:35.124Z",
      "location_count": 11,
      "location_summary": "Irvine, California • Long Beach, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03805841"
    },
    {
      "nct_id": "NCT02315066",
      "title": "Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "PF-04518600",
          "type": "DRUG"
        },
        {
          "name": "PF-04518600 plus PF-05082566",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2015-04-23",
      "completion_date": "2020-11-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-21",
      "last_synced_at": "2026-11-22T06:25:35.124Z",
      "location_count": 24,
      "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02315066"
    },
    {
      "nct_id": "NCT06188702",
      "title": "S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "MTAP-deleted Solid Tumors"
      ],
      "interventions": [
        {
          "name": "S095035",
          "type": "DRUG"
        },
        {
          "name": "TNG462",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Servier Bio-Innovation LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2024-04-29",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-22T06:25:35.124Z",
      "location_count": 5,
      "location_summary": "Lake Mary, Florida • Indianapolis, Indiana • Maumee, Ohio + 2 more",
      "locations": [
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Maumee",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06188702"
    },
    {
      "nct_id": "NCT03783403",
      "title": "A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "CC-95251",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2019-03-01",
      "completion_date": "2024-08-05",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-22T06:25:35.124Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03783403"
    }
  ]
}